别名 DIABETES INSIPIDUS AND MELLITUS WITH OPTIC ATROPHY AND DEAFNESS、DIDMOAD、DIDMOAD - Diabetes insipidus, diabetes mellitus, optic atrophy and deafness + [34] |
简介 A hereditary condition characterized by multiple symptoms including those of DIABETES INSIPIDUS; DIABETES MELLITUS; OPTIC ATROPHY; and DEAFNESS. This syndrome is also known as DIDMOAD (first letter of each word) and is usually associated with VASOPRESSIN deficiency. It is caused by mutations in gene WFS1 encoding wolframin, a 100-kDa transmembrane protein. |
作用机制 BAX调节剂 [+1] |
非在研适应症 |
最高研发阶段临床3期 |
首次获批国家/地区 加拿大 |
首次获批日期2022-06-14 |
作用机制 D2 receptor拮抗剂 [+1] |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
作用机制 MANF刺激剂 [+2] |
在研机构- |
在研适应症- |
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2024-01-01 |
申办/合作机构 |
开始日期2023-03-03 |
申办/合作机构 |
开始日期2021-11-26 |
申办/合作机构 |